Oncogenic messenger RNAs targeted by SIS-401-PACA (SIS-401-PACA targets)

Oncogenic messenger RNAs (mRNAs) targeted by SIS-401-PACA represent a set of transcripts that drive the progression and survival of pancreatic cancer cells. These mRNAs typically encode proteins involved in critical signaling pathways such as cell cycle regulation, apoptosis evasion, and metabolic reprogramming. By targeting these specific sequences, the therapeutic approach aims to silence the expression of drivers that are often difficult to inhibit with traditional small molecules or antibodies. SIS-401-PACA utilizes a microRNA (miRNA) payload designed to recognize and bind to these complementary mRNA sequences, facilitating their degradation through the cellular RNA interference machinery. This strategy allows for the simultaneous downregulation of multiple oncogenic drivers if the miRNA payload is designed to be multi-targeting or if the drug consists of a cocktail of sequences. The primary clinical focus for these targets is the treatment of pancreatic adenocarcinoma, where conventional therapies often fail due to the complex genetic landscape of the disease.

Other names

SIS-401-PACA miRNA targetsPancreatic cancer oncogenic mRNAsSIS-401-PACA payload targets

The drug SIS-401-PACA delivers a microRNA (miRNA) payload that binds to complementary sequences on specific oncogenic mRNAs, leading to their degradation or translational inhibition via the RNA-induced silencing complex (RISC).